HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN THE UNITED KINGDOM (UK)

被引：1
|
作者：
Oglesby, A. [1 ]
Pockett, R. D. [2 ]
McEwan, P. [2 ]
Chung, K. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Cardiff Res Consortium, Cardiff, S Glam, Wales
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66590-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A476 / A476
页数：1
相关论文
共 50 条
  • [31] Risk of skeletal-related events (SREs) following initial diagnosis of bony metastases in breast, lung, and prostate cancer
    Lamerato, Lois
    Glass, Andrew
    Wolff, Greg G.
    Richert-Boe, Kathryn E.
    Taneja, Charu
    Edelsberg, John
    Czapski, Natalie
    Chung, Karen
    Richhariya, Akshara
    Oster, Gerry
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer
    Klaassen, Zachary
    Howard, Lauren E.
    de Hoedt, Amanda
    Amling, Christopher L.
    Aronson, William J.
    Cooperberg, Matthew R.
    Kane, Christopher J.
    Terris, Martha K.
    Freedland, Stephen J.
    CANCER, 2017, 123 (09) : 1528 - 1535
  • [33] FACTORS PREDICTING SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Klaassen, Zachary
    Howard, Lauren
    de Hoedt, Amanda
    Amling, Christopher L.
    Aronson, William J.
    Cooperberg, Matthew R.
    Kane, Christopher J.
    Terris, Martha K.
    Freedland, Stephen J.
    JOURNAL OF UROLOGY, 2016, 195 (04): : E656 - E656
  • [34] Costs of skeletal-related events (SREs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with oral therapies.
    Engel-Nitz, Nicole
    Behl, Ajay S.
    Blauer-Peterson, Cori
    Li, Sophia S.
    Dawson, Nancy Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] The cost of treating skeletal-related events in patients with bone metastases secondary to breast, lung, or prostate cancer
    Barber, B.
    Oglesby, A.
    Lage, M. J.
    Harrison, D. J.
    Jun, S.
    VALUE IN HEALTH, 2008, 11 (03) : A69 - A69
  • [36] Skeletal-related events (SRE) prevented in breast cancer patients with bone metastases in the United States (US)
    Arellano, J.
    Chen, K.
    Halperin, M.
    Danese, M.
    CANCER RESEARCH, 2013, 73
  • [37] A multicenter, open-label study to determine the effect of intravenous zoledronic acid (ZOL) on pain and quality of life in patients with bone metastases with or without skeletal-related events (SREs) resulting from breast cancer (BC) and prostate cancer (PC).
    Al Farhat, Y. B.
    Cseh, J.
    Boer, K.
    Csepreghy, M.
    Pajor, L.
    Thurzo, L.
    Mangel, L.
    Esik, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Impact of skeletal-related events on survival in patients with prostate cancer metastatic to bones.
    McDougall, Jean A.
    Goulart, Bernardo Haddock Lobo
    Sullivan, Sean D.
    McCune, Jeannine S.
    Bansal, Aasthaa
    Karnopp, Andrew
    Fedorenko, Catherine R.
    Valderrama, Adriana
    Seal, Brian S.
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [39] The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC).
    Hadji, P.
    Ziller, M.
    Maurer, T.
    Muth, M.
    Ruebel, A.
    May, C.
    Birkholz, K.
    Gschwend, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] Health resource utilization (HRU) and cost associated with bone metastases (BMets) and skeletal related events (SREs) in patients (Pts) with prostate cancer (PC).
    Hagiwara, M.
    Atchison, C.
    Chung, K.
    Delea, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345